List of Excipients in Branded Drug PANTOPRAZOLE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	PANTOPRAZOLE SODIUM	pantoprazole sodium	0143-9284	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	PANTOPRAZOLE SODIUM	pantoprazole sodium	0143-9300	SODIUM HYDROXIDE
Baxter Healthcare Corporation	PANTOPRAZOLE SODIUM	pantoprazole sodium in 0.9% sodium chloride	0338-9644	EDETATE DISODIUM
Baxter Healthcare Corporation	PANTOPRAZOLE SODIUM	pantoprazole sodium in 0.9% sodium chloride	0338-9644	HISTIDINE
Baxter Healthcare Corporation	PANTOPRAZOLE SODIUM	pantoprazole sodium in 0.9% sodium chloride	0338-9644	SODIUM CHLORIDE
Baxter Healthcare Corporation	PANTOPRAZOLE SODIUM	pantoprazole sodium in 0.9% sodium chloride	0338-9644	WATER
STAT RX USA LLC	PANTOPRAZOLE SODIUM	pantoprazole sodium	16590-635	CALCIUM STEARATE

Generic Drugs Containing PANTOPRAZOLE

Company	Ingredient	NDC	Excipient
State of Florida DOH Central Pharmacy	pantoprazole	53808-1081	ALCOHOL
State of Florida DOH Central Pharmacy	pantoprazole	53808-1081	AMMONIA
State of Florida DOH Central Pharmacy	pantoprazole	53808-1081	BUTYL ALCOHOL
State of Florida DOH Central Pharmacy	pantoprazole	53808-1081	CALCIUM STEARATE
State of Florida DOH Central Pharmacy	pantoprazole	53808-1081	CROSPOVIDONE
State of Florida DOH Central Pharmacy	pantoprazole	53808-1081	FERRIC OXIDE YELLOW
State of Florida DOH Central Pharmacy	pantoprazole	53808-1081	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in PANTOPRAZOLE?

# Of NDCs	Excipient
14	ALCOHOL
14	AMMONIA
14	BUTYL ALCOHOL
14	CALCIUM STEARATE
14	CROSPOVIDONE
14	FERRIC OXIDE YELLOW
14	FERROSOFERRIC OXIDE

Pantoprazole Excipient Strategy and Commercial Opportunities

Last updated: September 14, 2026

Pantoprazole is a mature proton-pump inhibitor with limited opportunity for new-molecule exclusivity but meaningful commercial potential in formulation performance, modified-release delivery, pediatric dosing, intravenous stability, and regional product differentiation. The key technical requirement is protection of the acid-labile benzimidazole proton-pump inhibitor until intestinal release. The strongest excipient opportunities involve enteric polymers, moisture-control systems, coating efficiency, multiparticulate delivery, and preservative-free or low-excipient injectable products.

What excipient strategy is required for pantoprazole?

Pantoprazole requires an acid-protection strategy because gastric acid can degrade the active pharmaceutical ingredient before absorption. Oral products therefore use delayed-release tablets, capsules, or granules with an enteric barrier that remains intact in the stomach and dissolves at a higher intestinal pH.

The formulation architecture normally includes:

1. An immediate-release drug-containing core.
2. A seal coat or subcoat that separates pantoprazole from acidic or reactive coating components.
3. An enteric coating that resists gastric fluid.
4. Optional overcoating for mechanical protection, appearance, and process robustness.

Pantoprazole is commonly administered as pantoprazole sodium sesquihydrate. Excipients must preserve chemical stability, support manufacturability, and produce reproducible intestinal release.

Core formulation objectives

Objective	Excipient or technology response
Protect pantoprazole from gastric acid	Enteric polymers such as methacrylic acid copolymers or hypromellose phthalate
Limit drug-polymer interaction	Seal coat based on hypromellose or another neutral film former
Control tablet weight and compression	Mannitol, microcrystalline cellulose, lactose, or dibasic calcium phosphate, depending on compatibility
Improve disintegration	Crospovidone, croscarmellose sodium, or sodium starch glycolate
Maintain content uniformity	Povidone, copovidone, or optimized granulation fluid
Reduce moisture exposure	Low-water processing, protective film coatings, desiccant packaging, and moisture-barrier blisters
Improve coating adhesion	Hypromellose, polyvinyl alcohol, or specialized coating systems
Achieve consistent dissolution	Controlled enteric-polymer weight gain, plasticizer selection, and coating-process controls

The commercial objective is not simply to add excipients. It is to create a robust formulation that passes acid-stage dissolution, releases reproducibly in intestinal media, and remains stable through distribution.

What excipients are used in pantoprazole delayed-release tablets?

Pantoprazole delayed-release products commonly use a combination of fillers, binders, disintegrants, lubricants, film-forming agents, enteric polymers, plasticizers, and pigments. Exact compositions differ by manufacturer and market.

US labeling for Protonix delayed-release tablets identifies excipient classes including mannitol, crospovidone, povidone, calcium stearate, hypromellose, titanium dioxide, and iron oxide in certain strengths or coating systems (U.S. Food and Drug Administration [FDA], 2024a). Generic products may use different excipient systems while maintaining the same active ingredient, strength, dosage form, and release profile.

Common excipient categories

Fillers and compression aids

Mannitol is attractive because it provides good mouthfeel, relatively low hygroscopicity, and useful compression behavior. Microcrystalline cellulose can improve tablet strength and compactibility but may alter disintegration and moisture behavior. Lactose is widely used in oral solid dosage forms but requires compatibility and moisture-risk assessment.

For pantoprazole, the filler system should support low-moisture processing. Excess water or prolonged exposure to humidity can create stability problems for an acid-labile active ingredient.

Binders

Povidone and copovidone can improve granule strength and content uniformity. The binder level must be controlled because excessive binder can delay disintegration and alter dissolution after enteric coating.

Wet granulation may improve uniformity but increases exposure to water. Dry granulation or direct compression can reduce water exposure, although these approaches require suitable powder flow, compressibility, and segregation control.

Disintegrants

Crospovidone, croscarmellose sodium, and sodium starch glycolate can support rapid breakup after the enteric layer dissolves. The choice affects tablet porosity, disintegration time, and the risk of premature coating damage.

Crospovidone is frequently useful when rapid post-gastric disintegration is needed. Croscarmellose sodium can provide strong swelling and wicking performance but may require tighter control of ionic strength and moisture.

Lubricants

Calcium stearate and magnesium stearate reduce tooling friction. Excessive lubricant can reduce wettability and slow dissolution. Calcium stearate may be selected where a different hydrophobicity profile or processing performance is desired.

Lubricant concentration and blending time are important process variables. Over-lubrication can create a dissolution defect that is difficult to correct with coating changes.

What enteric coating systems are suitable for pantoprazole?

The enteric layer is the central excipient component in pantoprazole oral products. Suitable systems include methacrylic acid copolymers, hypromellose phthalate, hypromellose acetate succinate, and polyvinyl acetate phthalate. Methacrylic acid copolymers are widely used because their dissolution thresholds can be selected through polymer grade and formulation design.

Enteric polymer comparison

Polymer system	Commercial advantage	Main development issue
Methacrylic acid copolymer, higher-pH dissolving grade	Strong gastric resistance and intestinal targeting	Requires controlled coating weight and plasticization
Methacrylic acid copolymer, lower-pH dissolving grade	Earlier intestinal release	May provide less margin against gastric exposure
Hypromellose phthalate	Established enteric technology	Can require careful solvent and film-property control
Hypromellose acetate succinate	Flexible release-pH and film-property options	Supplier grade and substitution-level differences affect performance
Polyvinyl acetate phthalate	Good enteric protection	Less common platform for some modern aqueous coating processes
Ready-to-use aqueous dispersion	Simplifies manufacturing and reduces solvent handling	Higher risk of process sensitivity, tackiness, and drying defects

Plasticizers such as triethyl citrate, acetyl tributyl citrate, polyethylene glycol, or equivalent systems can improve film flexibility. Surfactants may improve coating dispersion and wetting but can affect permeability and dissolution.

Seal coats and subcoats

A seal coat is often commercially valuable because it separates pantoprazole from the enteric polymer. This can reduce direct contact with acidic functional groups and improve stability. Hypromellose is a common film-forming material for the subcoat.

A seal coat can also improve:

• Tablet surface smoothness.
• Enteric-coating adhesion.
• Resistance to coating defects.
• Uniformity of polymer distribution.
• Protection against moisture ingress.

The tradeoff is increased tablet weight, longer processing time, and potentially higher manufacturing cost.

What formulation patents protect pantoprazole products?

Pantoprazole's core chemical and basic product protection is no longer a material barrier to generic competition in the United States. The original Protonix product has faced generic competition for many years, and the principal commercial market is now driven by manufacturing cost, regulatory compliance, supply reliability, formulation quality, and channel access rather than basic active-ingredient exclusivity.

The main remaining intellectual-property opportunities are formulation-specific or platform-specific. These may include:

• Multiparticulate delayed-release systems.
• Stable aqueous suspensions.
• Pediatric granules.
• Orally disintegrating tablets.
• Specific enteric-coating combinations.
• Low-moisture manufacturing processes.
• Improved intravenous reconstitution or storage systems.
• Fixed-dose combinations.
• New salts, solvates, or particle-engineering approaches, subject to patentability and regulatory relevance.
• Manufacturing methods that reduce degradation or improve yield.

A formulation patent must provide more than a routine substitution of one pharmaceutically acceptable excipient for another. Commercially defensible claims are more likely when the excipient system produces an unexpected stability, dissolution, bioavailability, manufacturability, or storage benefit.

What is the FDA regulatory status of pantoprazole?

Pantoprazole is FDA-approved in delayed-release oral and intravenous dosage forms. Protonix delayed-release tablets are approved for conditions including erosive esophagitis associated with gastroesophageal reflux disease and maintenance of healing in adults. Pantoprazole sodium for injection is approved for short-term treatment in adults when oral therapy is not possible, including certain hypersecretory conditions (FDA, 2024a; FDA, 2024b).

The regulatory pathway depends on the product design:

Product concept	Likely US pathway
Conventional generic delayed-release tablet	ANDA under section 505(j)
Generic delayed-release granules or capsule	ANDA if pharmaceutically equivalent and therapeutically equivalent
New pediatric formulation with differentiated delivery	Potential 505(b)(2), depending on changes and supporting data
New fixed-dose combination	505(b)(2) or NDA pathway
Novel injectable presentation	505(b)(2) or ANDA, depending on reference-product equivalence
New indication using known pantoprazole	505(b)(2), NDA supplement, or other applicable pathway

FDA review focuses on pharmaceutical equivalence, bioequivalence, product quality, acid-stage resistance, buffer-stage release, stability, impurities, and manufacturing controls. A new excipient may require additional safety justification if it lacks adequate precedent in the proposed route, dose, or patient population (FDA, 2016).

When does pantoprazole lose exclusivity?

Pantoprazole lost practical US market exclusivity after expiration of its original patent estate and subsequent generic entry. The key commercial consequence is that excipient differentiation is now more important than molecule-level exclusivity.

Exclusivity and patent position

Protection category	Commercial position
Active ingredient and core product protection	Expired or no longer a meaningful US barrier
Original Protonix patents	Historical protection; not a current barrier to routine generic entry
Regulatory exclusivity	No current new-drug exclusivity for the established product
Orange Book relevance	Relevant to any listed patents for current reference products, but generic competition remains established
Formulation patents	Potentially relevant for new delivery systems or differentiated products
Manufacturing patents	Potentially relevant where process conditions create measurable quality or cost advantages
Pediatric or specialty products	May create narrower product-level differentiation if supported by new clinical or formulation data

Patent analysis should distinguish between expired core patents and later patents covering specific formulations, methods of use, or manufacturing processes. A patent on a particular excipient combination does not necessarily block a generic using a different coating system.

What commercial opportunities exist for pantoprazole excipients?

The strongest opportunities are in products that solve practical formulation or market-access problems rather than replicate a standard delayed-release tablet.

Pediatric granules and sprinkle products

Pediatric and swallowing-impaired patients may benefit from granules that can be administered with soft food or liquid. The excipient strategy must preserve enteric protection after dose manipulation and maintain dose uniformity.

Commercial barriers include:

• Palatability.
• Granule size and mouthfeel.
• Stability after opening.
• Compatibility with food vehicles.
• Accurate partial-dose administration.
• Child-resistant and caregiver-friendly packaging.

Multiparticulate products can support product differentiation under a 505(b)(2) strategy if the delivery system, dosing flexibility, or clinical use provides a meaningful distinction.

Orally disintegrating and rapidly dispersing products

An orally disintegrating product may improve administration for patients who cannot swallow tablets. Pantoprazole remains acid-labile, so the formulation must preserve enteric protection even when the dosage form rapidly disperses in the mouth.

Possible approaches include:

• Enteric-coated microgranules embedded in an orally disintegrating matrix.
• Taste-masked coated particles.
• Low-moisture direct-compression systems.
• Manually dispersible tablets containing protected granules.

The main development risks are premature release, gritty mouthfeel, loss of acid resistance during compression, and moisture-driven degradation.

Intravenous formulation improvement

Pantoprazole sodium for injection is typically supplied as a lyophilized product requiring reconstitution. The formulation contains a small excipient system compared with oral dosage forms. DailyMed labeling identifies edetate disodium and sodium hydroxide among formulation components for certain pantoprazole injection products (FDA, 2024b).

Commercial opportunities include:

• Ready-to-use presentations.
• Reduced reconstitution time.
• More convenient vial or bag configurations.
• Improved in-use stability.
• Lower particulate risk.
• Hospital pharmacy workflow improvements.
• Reduced packaging waste.

The main barriers are chemical stability, pH control, container-closure compatibility, extractables and leachables, sterilization, and the economics of hospital procurement.

Global low-cost delayed-release products

In emerging markets, cost-efficient enteric coating and stable packaging can improve access. Commercial strategies include:

• Aqueous rather than organic coating systems.
• Lower coating weight without loss of acid resistance.
• High-throughput pan coating.
• Local excipient sourcing.
• Blister packaging optimized for tropical climates.
• Reduced tablet weight and packaging volume.

These products must still meet dissolution and stability requirements in high-temperature and high-humidity conditions. Packaging is part of the excipient strategy because moisture-barrier performance can determine shelf life.

How strong is the pantoprazole formulation patent estate?

The formulation patent estate is moderate for new delivery systems but weak for routine generic delayed-release tablets. A standard tablet using familiar fillers, binders, disintegrants, lubricants, and enteric polymers is unlikely to create a durable competitive moat without a demonstrated technical effect.

Relative patent strength by opportunity

Opportunity	Patent strength potential	Commercial value
Conventional delayed-release tablet	Low	High volume, low margin
Novel enteric polymer combination	Moderate	Moderate if dissolution and stability improve
Pediatric multiparticulates	Moderate to high	High in specialized channels
Orally disintegrating dosage form	Moderate	Moderate
Ready-to-use injectable	Moderate to high	High in hospital settings
New fixed-dose combination	Moderate	Potentially high
Low-cost manufacturing process	Moderate	High if it lowers cost without quality loss
New salt or solid form	Variable	Dependent on patent validity and regulatory value

The most defensible claims typically connect the excipient system to measurable performance. Examples include improved acid resistance at reduced coating weight, reduced degradation under humidity stress, faster intestinal release after gastric transit, or improved reconstitution stability.

What patent litigation and Paragraph IV risks affect pantoprazole?

Pantoprazole has a mature generic market, so Paragraph IV risk is most relevant to later differentiated products rather than ordinary generic entry. A generic applicant may use Paragraph IV certification against an unexpired Orange Book-listed patent, but an applicant can also rely on Paragraph III certification or a statement that no relevant patent is listed.

For new pantoprazole formulations, litigation risk may arise from:

• Enteric-coated multiparticulate patents.
• Specific pediatric delivery systems.
• Fixed-dose combination patents.
• Method-of-use patents.
• Injectable presentation patents.
• Manufacturing-process patents.
• Patents covering a particular salt, polymorph, or particle-size distribution.

The key diligence question is whether the proposed formulation practices a valid, enforceable claim. A broad commercial description such as "enteric-coated pantoprazole" is not equivalent to a claim covering every enteric-coated pantoprazole product.

What Orange Book status applies to pantoprazole?

The Orange Book is relevant to FDA-approved pantoprazole reference products and any patents listed against those products. Protonix is the historical US reference brand, while multiple generic pantoprazole products are approved through ANDAs.

Because Orange Book listings and patent statuses can change, the legal analysis should be performed against the current FDA Orange Book record for the specific NDA and dosage form. The core market fact is stable: pantoprazole delayed-release tablets and injection products have established generic competition, and ordinary excipient substitution is not likely to restore molecule-level exclusivity (FDA, 2024c).

How does pantoprazole compare with omeprazole and esomeprazole?

Pantoprazole competes with omeprazole, esomeprazole, lansoprazole, and rabeprazole. All require formulation strategies that protect an acid-labile active ingredient, but their excipient systems and release behavior are not interchangeable.

Attribute	Pantoprazole	Omeprazole	Esomeprazole
Product class	Proton-pump inhibitor	Proton-pump inhibitor	S-isomer proton-pump inhibitor
Common oral technology	Delayed-release tablet or granule	Delayed-release capsule, tablet, or granule	Delayed-release tablet, capsule, or granule
Main formulation issue	Acid protection and stability	Acid protection and moisture sensitivity	Acid protection and stability
Generic competition	Established	Established	Established
Differentiation opportunity	Pediatric, injectable, coating, combination products	Broad formulation competition	Premium and specialty formulations
Excipient strategy	Low-moisture core, seal coat, enteric film	Multiparticulate and capsule systems	Enteric tablet and granule systems

Pantoprazole may offer a practical formulation position where a manufacturer has experience with delayed-release tablets and wants to add hospital injection, pediatric granules, or regional generic products without developing a new active ingredient.

What manufacturing and supply-chain barriers affect pantoprazole?

The principal manufacturing barriers are process control and stability rather than raw-material scarcity.

Important controls include:

• Pantoprazole assay and degradation products.
• Water activity and residual moisture.
• Granulation endpoint.
• Blend uniformity.
• Compression force.
• Seal-coat weight gain.
• Enteric-coat weight gain.
• Coating inlet and exhaust conditions.
• Acid-stage dissolution.
• Buffer-stage dissolution.
• Packaging moisture transmission.
• Stability under accelerated and long-term conditions.

Supplier qualification matters for enteric polymers because changes in molecular weight, substitution level, particle size, or dispersion properties can affect coating performance. A formulation that depends on a single polymer grade may face avoidable supply risk.

Dual sourcing is more difficult for specialized excipients than for standard fillers. The replacement material must match functional performance, not only compendial identity. A change in polymer supplier can require comparative coating studies, dissolution testing, stability work, and regulatory reporting.

What is the revenue exposure and commercial outlook for pantoprazole?

Pantoprazole is a high-volume, mature generic medicine. Revenue exposure is therefore concentrated in:

• Unit cost.
• Manufacturing yield.
• Product availability.
• Hospital contracts.
• Retail formulary position.
• Geographic registration.
• Product differentiation.
• Recall and supply interruption risk.

A conventional generic tablet is likely to face price competition. Higher-margin opportunities are more likely in specialty presentations, including pediatric products, sprinkle formulations, orally disintegrating systems, hospital-ready injectable products, and combination products.

The commercial case for a new excipient platform is strongest when it produces one or more of the following:

1. A differentiated FDA-approved dosage form.
2. Lower coating or manufacturing cost.
3. Better stability in hot and humid markets.
4. A clinically useful dosing or administration advantage.
5. Reduced hospital preparation time.
6. A defensible formulation or process patent.
7. A reliable supply advantage over incumbent products.

Key Takeaways

• Pantoprazole requires acid protection because the active ingredient is acid labile.
• Enteric coating, seal-coat design, moisture control, and dissolution performance are the central excipient issues.
• Mannitol, povidone, crospovidone, calcium stearate, hypromellose, titanium dioxide, and iron oxides appear in marketed pantoprazole tablet formulations, although generic compositions vary.
• The core pantoprazole patent position is no longer a meaningful barrier to ordinary US generic entry.
• New formulation patents may remain commercially relevant for pediatric granules, orally disintegrating products, injectable presentations, fixed-dose combinations, and manufacturing processes.
• The best commercial opportunities are differentiated dosage forms and lower-cost, higher-stability manufacturing systems.
• Excipient substitutions must be evaluated for acid-stage resistance, intestinal release, moisture sensitivity, stability, and supplier reproducibility.
• Pantoprazole competes in a mature proton-pump inhibitor market where commercial performance depends more on cost, supply, channel access, and formulation differentiation than on molecule-level exclusivity.

Frequently Asked Questions

Can pantoprazole be formulated without an enteric coating?

A conventional oral pantoprazole product generally requires acid protection. An uncoated tablet would expose the active ingredient to gastric acid and could fail stability, dissolution, and bioavailability requirements.

Which excipient is most important in pantoprazole tablets?

The enteric polymer system is usually the most critical excipient component because it controls gastric resistance and intestinal release. The seal coat is also important because it separates the active ingredient from potentially reactive coating components.

Is a pantoprazole orally disintegrating tablet commercially feasible?

Yes, but the product must contain protected particles or another delayed-release architecture. Rapid oral disintegration cannot compromise gastric resistance or produce unacceptable taste and mouthfeel.

Can a new pantoprazole excipient combination receive patent protection?

It can receive patent protection if the claimed combination is novel, nonobvious, adequately described, and linked to a credible technical advantage. Routine substitution of one common excipient for another is less likely to provide strong protection.

What is the most attractive pantoprazole formulation opportunity?

Pediatric multiparticulates, flexible sprinkle products, ready-to-use injectable presentations, and low-moisture enteric systems offer stronger differentiation than another conventional delayed-release tablet.

References

1. U.S. Food and Drug Administration. (2016). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for industry.

2. U.S. Food and Drug Administration. (2024a). Protonix (pantoprazole sodium) delayed-release tablets: Prescribing information. DailyMed.

3. U.S. Food and Drug Administration. (2024b). Pantoprazole sodium for injection: Prescribing information. DailyMed.

4. U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations. Orange Book.